Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 993

Sort by

Sort Order Select

Journal Articles

BCL2 and MCL1 inhibitors for hematologic malignancies

Andrew W. Roberts, Andrew H. Wei, David C. S. Huang

Blood (2021) 138 (13): 1120–1136.

https://doi.org/10.1182/blood.2020006785

Published: 2021

Journal Articles

How I treat pediatric acute myeloid leukemia

Jeffrey E. Rubnitz, Gertjan J. L. Kaspers

Blood (2021) 138 (12): 1009–1018.

https://doi.org/10.1182/blood.2021011694

Published: 2021

Journal Articles

Exploring the pathways to chronic lymphocytic leukemia

Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps

Blood (2021) 138 (10): 827–835.

https://doi.org/10.1182/blood.2020010029

Published: 2021

Journal Articles

To start and stop or just keep going?

John G. Gribben

Blood (2021) 138 (10): 819–820.

https://doi.org/10.1182/blood.2021012675

Published: 2021

Journal Articles

The essential reading list for AML: the m 6 A transcripts

Kamil R. Kranc

Blood (2021) 138 (1): 6–7.

https://doi.org/10.1182/blood.2021011755

Published: 2021

Journal Articles

YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m 6 A-dependent manner

Blood (2021) 138 (1): 71–85.

https://doi.org/10.1182/blood.2020009676

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia

Blood (2021) 137 (26): 3641–3655.

https://doi.org/10.1182/blood.2020007651

Published: 2021

Includes: Supplemental data

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

PI3K/BCL2: illusion or promise for RS?

Lukas P. Frenzel

Blood (2021) 137 (24): 3319–3321.

https://doi.org/10.1182/blood.2021011854

Published: 2021

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Scott Boiko, Theresa Proia, Maryann San Martin, Gareth P. Gregory, Michelle Min Wu, Neeraj Aryal, Maureen Hattersley, Wenlin Shao, Jamal C. Saeh, Stephen E. Fawell, Ricky W. Johnstone, Lisa Drew, Justin Cidado

Blood (2021) 137 (21): 2947–2957.

https://doi.org/10.1182/blood.2020008528

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting MCL-1 and BCL-2: a 1-2 punch

Jennifer R. Brown

Blood (2021) 137 (20): 2711–2712.

https://doi.org/10.1182/blood.2021012001

Published: 2021

Journal Articles

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Blood (2021) 137 (20): 2721–2735.

https://doi.org/10.1182/blood.2020010167

Published: 2021

Includes: Supplemental data

Journal Articles

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Neeta Bala Tannan, Mandana T. Manzari, Laurie Herviou, Mariana Da Silva Ferreira, Connor Hagen, Hiroto Kiguchi, Katia Manova-Todorova, Venkatraman Seshan, Elisa de Stanchina, Daniel A. Heller, Anas Younes

Blood (2021) 137 (15): 2057–2069.

https://doi.org/10.1182/blood.2020008017

Published: 2021

Includes: Supplemental data

Journal Articles

Requirement for antiapoptotic MCL-1 during early erythropoiesis

Meghan E. Turnis, Ewa Kaminska, Kaitlyn H. Smith, Brittany J. Kartchner, Peter Vogel, Jonathan D. Laxton, Richard A. Ashmun, Paul A. Ney, Joseph T. Opferman

Blood (2021) 137 (14): 1945–1958.

https://doi.org/10.1182/blood.2020006916

Published: 2021

Includes: Supplemental data

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Bcl-2 inhibition in DLBCL: “the times they are a-changing”?

Umberto Vitolo, Mattia Novo

Blood (2021) 137 (5): 577–579.

https://doi.org/10.1182/blood.2020008924

Published: 2021

Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Blood (2021) 137 (5): 600–609.

https://doi.org/10.1182/blood.2020006578

Published: 2021

Includes: Supplemental data

Journal Articles

Inverting the BTK-BCL2 order

Jennifer R. Brown

Blood (2020) 135 (25): 2205–2207.

https://doi.org/10.1182/blood.2020005886

Published: 2020

Journal Articles

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti, Piers Blombery, Tamia Nguyen, David A. Westerman, Bryone J. Kuss, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Mary Ann Anderson

Blood (2020) 135 (25): 2266–2270.

https://doi.org/10.1182/blood.2020004782

Published: 2020

Includes: Supplemental data

NARROW

BCL2 and MCL1 inhibitors for hematologic malignancies

How I treat pediatric acute myeloid leukemia

Exploring the pathways to chronic lymphocytic leukemia

To start and stop or just keep going?

The essential reading list for AML: the m 6 A transcripts

YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m 6 A-dependent manner

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

PI3K/BCL2: illusion or promise for RS?

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Targeting MCL-1 and BCL-2: a 1-2 punch

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Requirement for antiapoptotic MCL-1 during early erythropoiesis

Mutational landscape of gray zone lymphoma

Bcl-2 inhibition in DLBCL: “the times they are a-changing”?

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Inverting the BTK-BCL2 order

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only